Tune Therapeutics vs BillionToOne
Side-by-side comparison of AI visibility scores, market position, and capabilities
Epigenome editing company silencing disease-causing genes without permanent DNA cuts; raised $175M Series B led by Hevolution, NEA, and Regeneron Ventures; dosed first patient in Phase 1/2 for chronic hepatitis B with Tune-401.
About
Tune Therapeutics is an epigenome editing company that silences disease-causing genes without making permanent DNA cuts — a potentially safer approach than traditional gene editing for chronic diseases. The company raised $175 million in Series B financing led by Hevolution Foundation (the world's largest longevity-focused philanthropic fund), NEA, and Regeneron Ventures, and has dosed its first patient in Phase 1/2 clinical trials for Tune-401, targeting chronic hepatitis B.
IPO Nov 2025 (BLLN, Nasdaq); $273M raised; 508K+ tests in 2025; $293–299M revenue guidance FY2025.
About
BillionToOne is a leading molecular diagnostics company that has commercialized a proprietary technology platform—Quantitative Counting Templates (QCTs)—enabling detection and quantification of disease-related DNA at single base-pair resolution. This breakthrough in cell-free DNA (cfDNA) analysis underpins its two primary product lines: UNITY Screen for comprehensive prenatal genetic screening (covering carrier status, chromosomal conditions, and fetal risk) and Northstar Select for oncology therapy guidance and liquid biopsy.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.